Delving into the Latest Updates on Mycologics, Inc. with Synapse

Overview

ABSTRACTLeishmania major is an important trypanosomatid pathogen that causes leishmaniasis, which is a serious disease in much of the Old World. Current treatments include a small number of antimony compounds that, while somewhat effective, are limited by serious side effects. We have screened a small portion of a unique chemical library and have found at least three novel compounds that are effective against L. tarentolae and L. major in vitro and in a murine macrophage model of L. major infection. These compounds were effective in both assays at doses significantly lower than those of sodium stibogluconate (Pentostam) and represent possible candidates for drug development.

01 Feb 2003·Current opinion in investigational drugs (London, England : 2000)

New cell wall targets for antifungal drugs.

Review

Author: Nakata, Mitsunori ; Selitrennikoff, Claude P

Fungal infections in humans caused by filamentous moulds and yeasts continue to be serious and often life-threatening, especially among immunocompromised patients. One of the most immediate and unmet medical needs is the identification of new treatment options for invasive aspergillosis infection. The fungal cell wall, as the most obvious difference between human and fungal cells, represents an excellent target for antifungals. Cell wall carbohydrates are polymerized from uridine di-phospho sugars that are synthesized by several biochemical pathways. The pathways for the synthesis of these cell wall precursors represent unexplored targets for new antifungals that have modes of action that are different from currently used therapeutics. This review will focus on the identification of several new therapy targets and on assays to screen for inhibitors of enzymes critical to the synthesis of cell wall precursors.

Current Opinion in Investigational Drugs (Thomson Current Drugs)

New cell wall targets for antifungal drugs

Author: Nakata, Mitsunori ; Selitrennikoff, Claude P.

A review.Fungal infections in humans caused by filamentous molds and yeasts continue to be serious and often life-threatening, especially among immunocompromised patients.One of the most immediate and unmet medical needs is the identification of new treatment options for invasive aspergillosis infection.The fungal cell wall, as the most obvious difference between human and fungal cells, represents an excellent target for antifungals.Cell wall carbohydrates are polymerized from uridine di-phospho sugars that are synthesized by several biochem. pathways.The pathways for the synthesis of these cell wall precursors represent unexplored targets for new antifungals that have modes of action that are different from currently used therapeutics.This review will focus on the identification of several new therapy targets and on assays to screen for inhibitors of enzymes critical to the synthesis of cell wall precursors.

100 Deals associated with Mycologics, Inc.

Login to view more data

100 Translational Medicine associated with Mycologics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data